High throughput fragment-based drug screening

Throughput has been a long-lasting technical hurdle in fragment-based drug discovery. This innovation enabled the simutaneous selection millions of combinations of drug fragments in just a few hours.

• The drug target is used as a template to guide the discovery of its "favorite" inhibitors by sampling millions of small "drug fragments"
• We successfully discovered novel drug candidates against SARS-CoV-2 and cancer targets

• The screening can be performed in a regular biochemistry laboratory in just a few hours without specialty instrument and facility.
• A "plug-and-play" system that can be rapidly adapted for virtually any drug targets
• Discovery of novel chemotypes with broad patent space in drug discovery

• Drug discovery
• Probe discovery

• Novel small molecule agonists of insulin receptor (INSR) as anti-diabetes drugs (PCT/CN2024/088584)
• Novel small molecule inhibitors of SARS-CoV-2 non-structure protein 13 (NSP13) helicase (No. 202410265878)